CA3202073A1 - Pharmacological agents for treating conditions of the eye - Google Patents
Pharmacological agents for treating conditions of the eyeInfo
- Publication number
- CA3202073A1 CA3202073A1 CA3202073A CA3202073A CA3202073A1 CA 3202073 A1 CA3202073 A1 CA 3202073A1 CA 3202073 A CA3202073 A CA 3202073A CA 3202073 A CA3202073 A CA 3202073A CA 3202073 A1 CA3202073 A1 CA 3202073A1
- Authority
- CA
- Canada
- Prior art keywords
- ona
- alkyl
- hydrogen
- group
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113691P | 2020-11-13 | 2020-11-13 | |
| US63/113,691 | 2020-11-13 | ||
| US202163215818P | 2021-06-28 | 2021-06-28 | |
| US63/215,818 | 2021-06-28 | ||
| PCT/US2021/072405 WO2022104383A1 (en) | 2020-11-13 | 2021-11-15 | Pharmacological agents for treating conditions of the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202073A1 true CA3202073A1 (en) | 2022-05-19 |
Family
ID=81601792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202073A Pending CA3202073A1 (en) | 2020-11-13 | 2021-11-15 | Pharmacological agents for treating conditions of the eye |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240000812A1 (enExample) |
| EP (1) | EP4243798A4 (enExample) |
| JP (1) | JP2023549533A (enExample) |
| CA (1) | CA3202073A1 (enExample) |
| MX (1) | MX2023005675A (enExample) |
| WO (1) | WO2022104383A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872236B2 (en) | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| WO2025090994A1 (en) * | 2023-10-26 | 2025-05-01 | Plex Pharmaceuticals, Inc. | Compositions for treating cataracts and/or presbyopia eye diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE439863T1 (de) * | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| JP6068484B2 (ja) * | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダSom Innovation Biotech, S.L. | トランスサイレチン関連アミロイドーシスの新規療法 |
| WO2013098416A2 (fr) * | 2011-12-30 | 2013-07-04 | Ecole Nationale Superieure De Chimie De Clermont Ferrand | Composes anti-douleur |
| WO2014164667A1 (en) * | 2013-03-11 | 2014-10-09 | Georgetown University | Dengue and west nile virus protease inhibitors |
| US20160317474A1 (en) * | 2013-12-18 | 2016-11-03 | Emory University | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects |
| US11872236B2 (en) * | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
| EP3683618A1 (en) * | 2019-01-21 | 2020-07-22 | Essilor International (Compagnie Generale D'optique) | System and method for demonstrating an optical disorder |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| JP2024520837A (ja) * | 2021-06-08 | 2024-05-24 | プレックビジョン、バイオテクノロジーズ、リミテッド | ダニの抑制又は滅殺及び眼球乾燥症の治療におけるcyp450阻害剤の使用 |
-
2021
- 2021-11-15 WO PCT/US2021/072405 patent/WO2022104383A1/en not_active Ceased
- 2021-11-15 US US18/037,021 patent/US20240000812A1/en active Pending
- 2021-11-15 CA CA3202073A patent/CA3202073A1/en active Pending
- 2021-11-15 EP EP21893092.3A patent/EP4243798A4/en active Pending
- 2021-11-15 JP JP2023528761A patent/JP2023549533A/ja active Pending
- 2021-11-15 MX MX2023005675A patent/MX2023005675A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023005675A (es) | 2023-07-31 |
| EP4243798A1 (en) | 2023-09-20 |
| WO2022104383A1 (en) | 2022-05-19 |
| JP2023549533A (ja) | 2023-11-27 |
| US20240000812A1 (en) | 2024-01-04 |
| EP4243798A4 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7311162B2 (ja) | 炎症性障害の処置 | |
| ES2374336T3 (es) | Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo. | |
| CN112601513B (zh) | 治疗眼部疾病的药物 | |
| KR102017916B1 (ko) | 노안, 경도 원시 및 불규칙한 난시의 치료를 위한 조성물 및 방법 | |
| WO2022104383A1 (en) | Pharmacological agents for treating conditions of the eye | |
| EP3856176A2 (en) | Inhibitors of vap-1 | |
| TW200940052A (en) | Ophthalmic NSAIDs as adjuvants | |
| CN111629720A (zh) | 用于治疗眼科病况的组合物和方法 | |
| KR20180095928A (ko) | 노안의 치료를 위한 조성물 | |
| CN116963727A (zh) | 用于治疗眼部病症的药剂 | |
| CA2949910C (en) | Modulators of intracellular chloride concentration for treating neurodegenerative diseases with parkinsonian syndromes | |
| EP3976017A1 (en) | Pharmacological agents for treating protein aggregation diseases of the eye | |
| JP2021512847A (ja) | キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤 | |
| TW200817378A (en) | Compositions and methods for treating or preventing glaucoma or progression thereof | |
| HK40103320A (en) | Pharmacological agents for treating conditions of the eye | |
| WO2023278604A1 (en) | Pharmacological agents for treating ophthalmic diseases | |
| CN103826642B (zh) | 含有黄素腺嘌呤二核苷酸或其盐作为有效成分的角膜上皮细胞死亡的抑制剂 | |
| Cornel et al. | Novelties in medical treatment of glaucoma | |
| ES2377342T3 (es) | Remedio para enfermedades corneales | |
| US20240285623A1 (en) | Trpa1 channel antagonist compound for use in degenerative retinal diseases | |
| Mowatt et al. | Strategies for neuroprotection in glaucoma | |
| HK40050888A (en) | Pharmacological agents for treating ocular diseases | |
| CN119424422A (zh) | 眼科药物组合物、用途及其制剂 | |
| HK40086794A (en) | Method for treating myopia by vinpocetine | |
| HK40109101A (en) | A pharmaceutical composition for effectively delaying and treating myopia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250513 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250513 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251113 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260112 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260224 |